SAB Biotherapeutics (SABS) Expected to Announce Quarterly Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $0.12 million for the quarter.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $1.60 on Tuesday. SAB Biotherapeutics has a 1 year low of $1.45 and a 1 year high of $5.01. The firm has a fifty day moving average price of $2.19 and a 200-day moving average price of $2.87. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SABS shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Chardan Capital reiterated a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.